How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings

Zacks explains its Earnings ESP (Expected Surprise Prediction), which compares the Most Accurate Estimate to the Zacks Consensus to flag likely earnings surprises; a positive ESP combined with a Zacks Rank #3 (Hold) or better has historically corresponded to positive surprises 70% of the time and a 28.3% average annual return in a 10-year backtest. The note highlights Royalty Pharma (RPRX) — Zacks Rank #3, Most Accurate Estimate $0.96 vs consensus $0.95 (ESP +1.41%) ahead of an August 8, 2024 report — and CME Group (CME) — Zacks Rank #3, Most Accurate $2.41 vs consensus $2.40 (ESP +0.26%) with an October 23, 2024 report date — suggesting both have modest positive ESP signals that may presage upside surprises and could inform pre-earnings trading decisions.

Analysis

Market structure: Positive Earnings ESP signals (like RPRX +1.41% and CME +0.26%) concentrate upside into event-driven and quant strategies that trade revision momentum; winners are earnings-focused longs, data providers and options buyers who anticipate a beat, while short-dated options sellers and passive index holders are most exposed to volatility spikes. Competitive dynamics concentrate flows into names with measurable most-accurate-estimate deltas, increasing realized IV and bid/offer spreads around prints and favoring larger, liquid issuers (CME) over smaller, idiosyncratic royalty names (RPRX). Liquidity and demand for short-dated calls rise before prints, putting transient upward pressure on skew; in cross-assets, a surprise at CME could compress US-listed exchange equities and push small re-pricings in rates (OTC clearing margin), while a biopharma surprise (RPRX) maps to credit spreads on royalty financing and biotech equity vols.

Risk assessment: Tail risks include trial failure or adverse royalty litigation for RPRX (binary, can move price >30% in 48 hours) and regulatory/back-office incidents or fee changes for CME (operational or competition risk, 10-25% shock). Time horizons: immediate (days) dominated by IV and flow; short-term (weeks) by guidance and analyst revisions; long-term (quarters) by secular cash flows and interest-rate driven discounting (a 100bp rise in term yield reduces royalty valuations materially). Hidden dependencies: analyst concentration (few Most Accurate Estimate authors), buyback timing, and derivative positioning that can amplify moves; catalysts include FDA news, volume/fee announcements at exchanges, and macro rate surprises.

Key Decisions for Investors

• Consider establishing a 2–3% long position in RPRX only if Zacks ESP ≥ +1% and current IV rank <50; implement via a 45–90 day call-debit spread (buy 1 call, sell a higher-strike call) sized to limit downside to 1–3% of portfolio value, enter 3–10 trading days pre-earnings and close one trading day before the print or hold up to 10 trading days post-print if beat and guidance is upgraded by ≥5%.
• Initiate a 1–2% pair trade long CME / short ICE equal-notional if CME exhibits persistent positive analyst revisions (ESP > +0.5% and 3+ upward Most Accurate revisions in 30 days); target 10–15% relative outperformance over 1–3 months, set a 6% stop-loss on either leg and rebalance monthly based on revision flow.
• Avoid naked short premium into earnings for biotech royalty names; reduce short-dated naked-put exposure by 50% for names like RPRX within 30 days of earnings or known clinical/legal catalysts to limit >30% idiosyncratic tail risk.
• Use options defensively: for modest ESP signals (0–2%) favor buying call debit spreads 40–60 DTE sized 0.5–1% notional to cap IV-crush losses; only scale to long single calls (90 DTE) when ESP > +3% or when most-accurate-estimate changes exceed consensus by >5%.